Chemically induced hepatocyte-derived liver progenitors for liver disease: From laboratory research to clinical translation

Chemically induced hepatocyte-derived liver progenitors have emerged as a promising platform for liver regenerative medicine. In 2017, Katsuda et al. demonstrated that a combination of three small molecules—Y-27632, A-83-01, and CHIR99021—could convert mature rodent hepatocytes into proliferative, bipotent liver progenitor cells. Subsequent studies extended this concept to human hepatocytes using modified combinations of small molecules and growth factors, generating expandable progenitor populations with hepatic and biliary differentiation potential. Preclinical studies have demonstrated therapeutic effects of hepatocyte-derived liver progenitors in models of liver fibrosis, cirrhosis, acute liver injury, impaired regeneration, metabolic liver disease, and inherited metabolic disorders. Large-animal studies have further supported their feasibility and safety. More recently, a first-in-human study of human hepatocyte-derived liver progenitors in patients with cirrhosis demonstrated initial safety and feasibility, while an autologous clinical trial has entered recruitment in Japan. Further standardized and controlled clinical studies will be essential to establish the efficacy and long-term safety of these cells and to define their role in future liver regenerative therapies.

Authors

Institutions

Publication Details

Published
2026-11-22
DOI
https://doi.org/10.69854/crm.2026.0064
Primary Topic
Liver physiology and pathology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chemically induced hepatocyte-derived liver progenitors for liver disease: From laboratory research to clinical translation

Yumeng Zhang, Asuma Hata
Liver physiology and pathology
article

Chemically induced hepatocyte-derived liver progenitors for liver disease: From laboratory research to clinical translation

Yumeng Zhang, Asuma Hata
article en

Abstract

Chemically induced hepatocyte-derived liver progenitors have emerged as a promising platform for liver regenerative medicine. In 2017, Katsuda et al. demonstrated that a combination of three small molecules—Y-27632, A-83-01, and CHIR99021—could convert mature rodent hepatocytes into proliferative, bipotent liver progenitor cells. Subsequent studies extended this concept to human hepatocytes using modified combinations of small molecules and growth factors, generating expandable progenitor populations with hepatic and biliary differentiation potential. Preclinical studies have demonstrated therapeutic effects of hepatocyte-derived liver progenitors in models of liver fibrosis, cirrhosis, acute liver injury, impaired regeneration, metabolic liver disease, and inherited metabolic disorders. Large-animal studies have further supported their feasibility and safety. More recently, a first-in-human study of human hepatocyte-derived liver progenitors in patients with cirrhosis demonstrated initial safety and feasibility, while an autologous clinical trial has entered recruitment in Japan. Further standardized and controlled clinical studies will be essential to establish the efficacy and long-term safety of these cells and to define their role in future liver regenerative therapies.

Vol. 1(1)
Hokuto Hospital (JP)
Liver physiology and pathology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon